A lighter Balance Sheet after China
How did Genus (LSE:GNS), the animal genetics group behind the PIC and ABS brands, manage to cut its net Debt so sharply in a single year? The answer sits largely in a transaction completed in January 2026, when the company reorganised its pig genetics Business in China into a joint venture. This article examines what the September full-year results show about that deal, underlying trading and remaining uncertainties.
What Genus does
Genus is a London-listed company headquartered in Basingstoke. It supplies breeding animals and genetic material to livestock producers in more than 24 countries. Its porcine division, Genus PIC, earns Revenue from breeding stock and royalties linked to the genetic improvement it delivers to pork producers. Its bovine division, Genus ABS, sells dairy and beef genetics, including sexed semen, to cattle farmers. The group also funds R&D, most prominently its PRRS-resistant pig (PRP) gene edit, which is designed to protect pigs against a costly respiratory disease.
The September results and the China deal
On 10 September 2026, Genus published preliminary results for the year ended 30 June 2026. The company reported that net debt fell to £71.8m from £228.2m a year earlier, with Leverage dropping to 0.4 times EBITDA from 1.5 times. Interest Cover improved to 12 times from 8 times.
The key driver was the PIC China joint venture with Beijing Capital Agribusiness (BCA). According to the announcement, Genus retained a 49% holding and received net cash proceeds of £97.7m after Withholding tax and costs. The deal also produced a £204.1m gain, which is why statutory profit before tax jumped to £310.5m from £28.5m. Genus additionally recorded a £5.6m milestone payment from BCA.
Alongside the results, the board announced a £60m share buyback to be executed during the 2027 financial year. Separately, on 30 September 2026, the company said it would issue 450,000 new shares to its employee benefit trust to satisfy awards under its share plans.
Underlying trading
Stripping out the one-off gain, the picture was steadier. Revenue slipped 2% to £658.1m, but adjusted operating profit rose 17% to £94.8m, and adjusted profit before tax increased 35% to £100.2m. Adjusted Earnings Per Share reached 110.3p and free Cash Flow rose 52% to £62.0m. The full-year Dividend was lifted 10% to 35.2p.
Within the divisions, PIC adjusted operating profit excluding joint ventures increased to £109.9m, with volumes up 12% including joint ventures. ABS lifted adjusted operating profit excluding joint ventures to £22.6m, helped by £9.0m of in-year benefit from its Value Acceleration Programme, and its Operating Margin improved to 7.5%.
Risks and what to watch
The company was candid about headwinds. It cited PRRS outbreaks affecting North American pork producers in the second half, Chinese pork prices described as significantly below break-even for much of the year, low Brazilian pork prices and subdued global dairy markets. It also noted that Chinese restrictions on US bovine genetics effectively closed that market during the year.
For the 2027 financial year, management expects constant-currency adjusted profit before tax to be in line with consensus and moderately higher than normalised 2026 adjusted profit before tax of £90.3m, with the year weighted to the second half. Progress on PRP matters too: the company reported approvals or positive determinations in Argentina, Canada, Uruguay and Peru, with work continuing towards Mexico and Japan, and PRP spending rose to £11.6m.
Conclusion
Genus cut its net debt mainly because the China joint venture turned part of its PIC business into cash while preserving a 49% interest. Combined with higher free cash flow, this gave the board room to raise the dividend and launch a buyback. Whether that balance sheet strength translates into further profit growth depends on disease, pork pricing and regulatory progress for PRP.
_11_18_2026_09_42_19_750506.jpg)
_11_18_2026_09_43_10_583784.jpg)




Please wait processing your request...